BUSINESSJul 2 · 11:00 UTCSCMP WORLDJulie Zhang

China AI drug-design deals swell as US scrutiny mounts

Chinese AI-driven drug-design firms are securing global deals despite US scrutiny, with out-licensing deals reaching $75 billion in the first five months of 2026, up from zero before 2020.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Linda ShupersonHSBCorganizationChinaplaceUnited StatesplaceAI drug-designtopicBiotech companiestopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJul 2 · 11:00 UTC
China AI drug-design deals swell as US scrutiny mounts
BUSINESSJun 8 · 12:40 UTC
Incyte strikes up to $2bn deal for blood disorder biotech
HEALTHApr 16 · 09:00 UTC
Drugmakers raised prices on hundreds of drugs despite Trump deals, report finds
HEALTHMay 19 · 13:23 UTC
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
BUSINESSMay 12 · 07:48 UTC
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs